Skip to main content

Table 3 Patient information for predominant histological subtypes in pathological stage I

From: The prognostic impact of lung adenocarcinoma predominance classification relating to pathological factors in lobectomy, the Japanese Joint Committee of Lung Cancer Registry Database in 2010

  Total Group A
(AIS + MIA)
Group B
(Lepidic)
Group C
(Papillary + acinar
 + variant)
Group D
(Solid + micropapillary)
p-value
n 2165 304 469 1242 150  
Sex (male/Female), n (%) 1,058/1,107 119/185 (39.1%) 199/270 (42.4%) 635/608 (51.1%) 98/52 (65.3%)  < 0.001
Age, mean ± SD 66.76 ± 9.02 66.49 ± 9.67 67. 65 ± 8.18 66.55 ± 9.13 66.19 ± 9.23 0.201
Smoking history ( ±), n (%) 1046/1060 (49.7%) 110/187 (37.0%) 188/269 (41.1%) 642/563 (53.3%) 106/41 (72.1%)  < 0.001
Operation time (min.), mean ± SD 201.1 ± 64.30 203.47 ± 62.70 195.27 ± 64.24 203.56 ± 65.35 194.17 ± 57.46 0.028
Invasion, n (%)
   Lymphatic vessel invasion ( ±) 371/1566 (19.2%) 0/265 (0.0%) 52/383 (12.0%) 277/823 (25.2%) 42/95 (30.7%)  < 0.001
   Vascular invasion ( ±) 350/1593 (18.0%) 0/267 (0.0%) 36/400 (8.3%) 248/853 (22.5%) 66/73 (47.5%)  < 0.001
   Pleural invasion ( ±) 383 /1770 (17.8%) 0/301 (0.0%) 51/416 (10.9%) 291/944 (23.6%) 41/109 (27.3%)  < 0.001
 EGFR mutation ( ±) 459/498 (48.0%) 64/42 (60.4%) 102/74 (58.0%) 284/325 (46.6%) 9/57 (13.6%)  < 0.001
 Adjuvant therapy ( ±) 563/1587 (26.2%) 24/278 (7.9%) 116/349 (24.9%) 378/857 (30.6%) 45/103 (30.4%)  < 0.001
 Pathological stage IA/IB 1431/734 (66.1%) 281/23 (92.4%) 319/150 (68.0%) 749/493 (60.3%) 82/68 (54.7%)  < 0.001